Gene Logic Inc. (GLGC) To Build Custom Equine Gene Expression Database For Genetraks Pty Ltd 
10/19/2005 5:10:25 PM

Gene Logic's Expertise in Gene Expression Data Generation and Bioinformatics Analysis Basis for Agreement

GAITHERSBURG, Md.--(BUSINESS WIRE)--Nov. 10, 2003-- Gene Logic Inc. (Nasdaq:GLGC - News) reported today it has entered a service agreement with Genetraks Pty., Ltd. to develop a custom equine gene expression data resource. Genetraks is a venture-funded biotechnology company currently based in Australia focused on developing new technologies for improving the diagnosis of disease for, and determining the health status of, performance animals, primarily horses. Financial details of this multiyear service agreement were not disclosed.

Under terms of the agreement, Gene Logic will build for Genetraks a database of genomic content from equine samples and related clinical information using custom microarrays provided by Genetraks. The agreement reflects Gene Logic's recognized leadership in gene expression data generation and bioinformatics analysis, as well as the extensive Quality Assurance standards and protocols the Company has in place for the collection, preparation and handling of tissue samples for use in microarray analysis. Genetraks will use this gene expression reference data set in developing diagnostics and performance monitoring technologies to expand the understanding of states of normal and diseased equine biology.

Commenting on the agreement, Larry Tiffany, Vice President, Business Development International, for Gene Logic, said, "This agreement illustrates the ways in which Gene Logic's core competencies in gene expression data generation and bioinformatics analysis can be adapted to meet particular needs and add significant value to the R&D efforts of an emerging biotechnology company like Genetraks. We look forward to being a significant catalyst in enabling Genetraks to achieve their goals of applying leading genomics technologies to a new, emerging market opportunity."

Dr. Roslyn Brandon, Chief Executive Officer for Genetraks, said, "We are delighted to be working with Gene Logic and to be taking advantage of their expertise in microarray data generation and sophisticated bioinformatics capabilities in developing this unique, highly focused reference resource for equine biology. Genetraks is committed to creating leading diagnostics for this industry using new technologies and I can think of no better partner than Gene Logic with whom to address this untapped market niche."

Gene Logic Overview

Gene Logic is a contract service provider to pharmaceutical, biotechnology, and institutional researchers worldwide combining extensive experience in sample collection and data analysis of gene expression information and expertise in preclinical safety and pharmacology studies and clinical trial consulting services. Service offerings are designed to improve the predictive value of research and pharmaceutical product development success rates. Visit or call toll-free - 1/800/GENELOGIC.

Genetraks Overview

Genetraks, a venture-funded biotechnology company currently based in Australia, is developing cutting-edge technologies for performance animals and athletes. Genetraks initial market focus is the Thoroughbred racehorse and is developing better tests and information for veterinarians, owners and trainers to manage horses to peak performance, based on leading gene expression and bioinformatics analysis technologies. Genetraks technology, based on gene expression data as opposed to bloodline and heritage trait data, will allow earlier disease diagnosis and monitoring of horses during training; the racing season; neonatal development; and before, during and after travel and quarantine. For additional company information, visit


Gene Logic Inc. Investors/Media: Robert G. Burrows, 301-987-1824

Source: Gene Logic Inc.